Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Beyondspring Inc (BYSI)

Beyondspring Inc (BYSI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 65,792
  • Shares Outstanding, K 41,120
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,120 K
  • EBIT $ -9 M
  • EBITDA $ -8 M
  • 60-Month Beta 0.56
  • Price/Sales N/A
  • Price/Cash Flow 14.17
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 118.78% (+1.30%)
  • Historical Volatility 73.06%
  • IV Percentile 22%
  • IV Rank 14.64%
  • IV High 646.81% on 04/10/25
  • IV Low 28.25% on 11/20/25
  • Expected Move (DTE 18) 0.0425 (2.66%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 8
  • Volume Avg (30-Day) 10
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 400
  • Open Int (30-Day) 374
  • Expected Range 1.5575 to 1.6425

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3100 +22.14%
on 03/03/26
1.8500 -13.51%
on 03/18/26
+0.2500 (+18.52%)
since 02/27/26
3-Month
1.2100 +32.23%
on 02/27/26
1.8500 -13.51%
on 03/18/26
-0.2400 (-13.04%)
since 12/26/25
52-Week
0.9800 +63.27%
on 04/07/25
3.4400 -53.49%
on 06/17/25
+0.1000 (+6.67%)
since 03/27/25

Most Recent Stories

More News
BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026

FLORHAM PARK, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for...

BYSI : 1.6500 (+3.12%)
BeyondSpring Files 2025 Annual Report on Form 10-K

FLORHAM PARK, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for...

BYSI : 1.6500 (+3.12%)
BeyondSpring Reports 2025 Year-End Financial Results

Plinabulin (BeyondSpring's Lead Program): Phase 3 Survival Benefit Confirmed: Plinabulin combined with docetaxel demonstrated statistically significant overall survival benefit vs. standard of care...

BYSI : 1.6500 (+3.12%)
BeyondSpring Reports 2025 Year-End Financial Results

Plinabulin (BeyondSpring's Lead Program): Phase 3 Survival Benefit Confirmed: Plinabulin combined with docetaxel demonstrated statistically significant overall survival benefit vs. standard of care...

BYSI : 1.6500 (+3.12%)
BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference

FLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today...

BYSI : 1.6500 (+3.12%)
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path

Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a late-stage candidate showing survival improvement in...

BYSI : 1.6500 (+3.12%)
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025

In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing Plinabulin...

BYSI : 1.6500 (+3.12%)
BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate Update

Two SITC 2025 presentations: First-in-class dendritic cell (DC) maturation agent Plinabulin drives immune re-sensitization in metastatic NSCLC patients who had progressed after PD-1/L1 inhibitors with...

BYSI : 1.6500 (+3.12%)
BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment

ASCO 2025 presentation: First-in-class agent Plinabulin drives immune re-sensitization in NSCLC patients progressed to PD-1/L1 therapies Med  (Cell Press) Publication with MD Anderson Collaboration...

BYSI : 1.6500 (+3.12%)
BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure

BYSI : 1.6500 (+3.12%)

Business Summary

BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Company's lead product consists of into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced...

See More

Key Turning Points

3rd Resistance Point 1.6733
2nd Resistance Point 1.6367
1st Resistance Point 1.6183
Last Price 1.6500
1st Support Level 1.5633
2nd Support Level 1.5267
3rd Support Level 1.5083

See More

52-Week High 3.4400
Fibonacci 61.8% 2.5003
Fibonacci 50% 2.2100
Fibonacci 38.2% 1.9197
Last Price 1.6500
52-Week Low 0.9800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.